The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released today.
The second progress report from the AMR Industry Alliance, a collection of companies and trade associations representing the pharmaceutical, biotechnology, generics, and diagnostics industries, says that while industry investment has resulted in a robust preclinical pipeline of new compounds and rapid diagnostic tests, many of these products may never reach patients unless governments take action to improve market conditions and encourage investment for new antibiotics.
The companies in the coalition are responsible for roughly one third of the global antibiotic supply chain, and nearly 50% of the AMR-related products in preclinical development. They say they can’t sustain a viable pipeline of products to address the growing threat of drug-resistant infections on their own.
“Discovering new and effective ways to leverage positive preclinical pipeline results and working together to ensure that late-stage antimicrobial drug discovery and development is better supported are vital,” AMR Industry Alliance chair Thomas Cueni, the director-general of the International Federation of Pharmaceutical Manufacturers & Associations, said in a press release.
Challenging market conditions
Read more at CIDRAP…